国际眼科杂志2018，Vol.18Issue(6)：1089-1092,4.DOI:10.3980/j.issn.1672-5123.2018.6.25
曲安奈德与雷珠单抗辅助治疗弥漫性糖尿病性黄斑水肿的疗效比较
Clinical efficacy of triamcinolone acetonide and Ranibizumab in the treatment of diabetic diffuse macular edema
摘要
Abstract
· AIM:To compare the clinical curative effect of triamcinolone acetonide and Ranibizumab on diffuse diabetic macular edema (DME).· METHODS:We collected 84 cases of patients with diffuse DME treated in our hospital from February 2016 to May 2017.According to 1:1 matching method,they were divided into Ⅰ,Ⅱ groups.They were all treated with laser photocoagulation.Preoperative auxiliary application of triamcinolone acetonide was given to Group Ⅰ,while Group Ⅱ received preoperative application of ranibizumab.After treatment,the efficacy of the two groups were analyzed and compared.· RESULTS:The total clinical efficiency of Group Ⅱ at 3mo after treatment was 93％,higher than that of Group Ⅰ (77％;x2 =4.981,P =0.025).Compared with before treatment,BCVA and CMT of the two groups at each time after treatment were significantly improved (P＜ 0.05).BCVA of Group Ⅱ at 1 and 3mo after treatment was better than that of Group Ⅰ (P＜0.05);CMT of Group Ⅱ at 1,3 and 6mo after treatment improved more than that of Group Ⅰ,with significant difference (P ＜ 0.05);occurrence rate of adverse reactions Group Ⅰ and Group Ⅱ were 17％ and 13％ with no significant statistical difference (X2 =0.243,P=0.621).There were no serious adverse reactions such as retinal detachment,endophthalmitis or cataract in the two groups.· CONCLUSION:Compared with triamcinolone acetonide,the effect of ranibizumab on diffuse diabetic macular edema is better,and has high clinical value.关键词
糖尿病弥漫性黄斑水肿/曲安奈德/雷珠单抗/激光光凝术Key words
diffuse diabetic macular edema/triamcinolone acetonide/ranibizumab/laser photocoagulation引用本文复制引用
谢碧华,何宇,辛梅,陈卓..曲安奈德与雷珠单抗辅助治疗弥漫性糖尿病性黄斑水肿的疗效比较[J].国际眼科杂志,2018,18(6):1089-1092,4.基金项目
四川省中医药科学技术研究专项项目(No.2016C026) （No.2016C026）
Sichuan Provincial Science and Technology Research Project on Traditional Chinese Medicine (No.2016C026) （No.2016C026）
